ArticleRadiology case reports2026
Neonatal osteogenesis imperfecta revealed by antenatal fractures: A case report.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteogenesis imperfecta (OI) is a rare genetic disorder of connective tissue, primarily caused by mutations in the COL1A1 and COL1A2 genes encoding type I collagen. We describe a male neonate diagnosed with OI after presenting with multiple antenatal and postnatal fractures. Prenatal ultrasound revealed intrauterine growth restriction and long-bone deformities. Postnatal clinical and radiological evaluations demonstrated diffuse osteopenia and multiple diaphyseal fractures. Genetic analysis identified a heterozygous COL1A2 (p.Gly358Ser) mutation consistent with type II OI. The patient was treated with intravenous zoledronic acid and showed was well tolerated. This case highlights the diagnostic and therapeutic challenges associated with severe neonatal OI. Early recognition, genetic confirmation, and multidisciplinary management are essential to improving survival and quality of life. Novel approaches including anti-sclerostin antibodies, TGF-β inhibitors, and emerging gene-editing therapies offer promising perspectives for the future management of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.